PACAP signaling exerts opposing effects on neuroprotection and neuroinflammation during disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis

Neurobiology of Disease

Volumn 54, Issue , 2013, Pages 32-42

  Ringer, Cornelia ^a   Büning, Luisa Sybille ^a   Schäfer, Martin K H ^a   Eiden, Lee E ^b   Weihe, Eberhard ^a   Schütz, Burkhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Amyotrophic lateral sclerosis; Microglia; Neuroinflammation; Neuropeptide; Neuroprotection; Parasympathetic; Sympathetic

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; MESSENGER RNA; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE GENE; ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR GENE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE INDUCTION; GENE LOCATION; GENE MUTATION; MALE; MOTOR PERFORMANCE; MOUSE; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VPAC1 GENE; VPAC2 GENE; WILD TYPE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MOTOR NEURONS; NERVE DEGENERATION; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE;

EID: 84875335631     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.02.010     Document Type: Article

References (73)

1. Abad C., Tan Y.V., Lopez R., Nobuta H., Dong H., Phan P., Feng J.M., Campagnoni A.T., Waschek J.A. Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:19555-19560.
2. Appel S.H., Beers D.R., Henkel J.S. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?. Trends Immunol. 2010, 31:7-17.
3. Arimura A., Somogyvári-Vigh A., Miyata A., Mizuno K., Coy D.H., Kitada C. Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 1991, 129:2787-2789.
4. Armstrong B.D., Hu Z., Abad C., Yamamoto M., Rodriguez W.I., Cheng J., Tam J., Gomariz R.P., Patterson P.H., Waschek J.A. Lymphocyte regulation of neuropeptide gene expression after neuronal injury. J. Neurosci. Res. 2003, 74:240-247.
5. Armstrong B.D., Abad C., Chhith S., Cheung-Lau G., Hajji O.E., Nobuta H., Waschek J.A. Impaired nerve regeneration and enhanced neuroinflammatory response in mice lacking pituitary adenylyl cyclase activating peptide. Neuroscience 2008, 151:63-73.
6. Baltadzhieva R., Gurevich T., Korczyn A.D. Autonomic impairment in amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2005, 18:487-493.
7. Beers D.R., Henkel J.S., Xiao Q., Zhao W., Wang J., Yen A.A., Siklos L., McKercher S.R., Appel S.H. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:16021-16026.
8. Beers D.R., Henkel J.S., Zhao W., Wang J., Appel S.H. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15558-15563.
9. Bogaert E., d'Ydewalle C., Van Den Bosch L. Amyotrophic lateral sclerosis and excitotoxicity: from pathological mechanism to therapeutic target. CNS Neurol. Disord. Drug Targets 2010, 9:297-304.
10. Boillée S., Vande Velde C., Cleveland D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:39-59.
11. Ceraudo E., Tan Y.V., Nicole P., Couvineau A., Laburthe M. The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor. J. Mol. Neurosci. 2008, 36:245-248.
12. Chen W.H., Tzeng S.F. Pituitary adenylate cyclase-activating polypeptide prevents cell death in the spinal cord with traumatic injury. Neurosci. Lett. 2005, 384:117-121.
13. Chen Y., Samal B., Hamelink C.R., Xiang C.C., Chen M., Vaudry D., Brownstein M.J., Hallenbeck J.M., Eiden L.E. Neuroprotection by endogenous and exogenous PACAP following stroke. Regul. Pept. 2006, 137:4-19.
14. Clement A.M., Nguyen M.D., Roberts E.A., Garcia M.L., Boillée S., Rule M., McMahon A.P., Doucette W., Siwek D., Ferrante R.J., Brown R.H., Julien J.P., Goldstein L.S., Cleveland D.W. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003, 302:113-117.
15. Dejda A., Sokołowska P., Nowak J.Z. Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacol. Rep. 2005, 57:307-320.
16. Dejda A., Seaborn T., Bourgault S., Touzani O., Fournier A., Vaudry H., Vaudry D. PACAP and a novel stable analog protect rat brain from ischemia: insight into the mechanisms of action. Peptides 2011, 32:1207-1216.
17. Delgado M., Jonakait G.M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia 2002, 39:148-161.
18. Delgado M., Leceta J., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. J. Leukoc. Biol. 2003, 73:155-164.
19. Dickson L., Finlayson K. VPAC and PAC receptors: from ligands to function. Pharmacol. Ther. 2009, 121:294-316.
20. Dupuis L., Pradat P.F., Ludolph A.C., Loeffler J.P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011, 10:75-82.
21. Fahrenkrug J., Hannibal J. Neurotransmitters co-existing with VIP or PACAP. Peptides 2004, 25:393-401.
22. Fuchs A., Ringer C., Bilkei-Gorzo A., Weihe E., Roeper J., Schütz B. Downregulation of the potassium chloride cotransporter KCC2 in vulnerable motoneurons in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2010, 69:1057-1070.
23. Goursaud S., Focant M.C., Berger J.V., Nizet Y., Maloteaux J.M., Hermans E. The VPAC2 agonist peptide histidine isoleucine (PHI) up-regulates glutamate transport in the corpus callosum of a rat model of amyotrophic lateral sclerosis (hSOD1G93A) by inhibiting caspase-3 mediated inactivation of GLT-1a. FASEB J. 2011, 25:3674-3686.
24. Grimaldi M., Cavallaro S. Functional and molecular diversity of PACAP/VIP receptors in cortical neurons and type I astrocytes. Eur. J. Neurosci. 1999, 11:2767-2772.
25. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
26. Haenggeli C., Kato A.C. Differential vulnerability of cranial motoneurons in mouse models with motor neuron degeneration. Neurosci. Lett. 2002, 335:39-43.
27. Hamelink C., Tjurmina O., Damadzic R., Young W.S., Weihe E., Lee H.W., Eiden L.E. Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:461-466.
28. Hannibal J. Pituitary adenylate cyclase-activating peptide in the rat central nervous system: an immunohistochemical and in situ hybridization study. J. Comp. Neurol. 2002, 453:389-417.
29. Hayar A., Bryant J.L., Boughter J.D., Heck D.H. A low-cost solution to measure mouse licking in an electrophysiological setup with a standard analog-to-digital converter. J. Neurosci. Methods 2006, 153:203-207.
30. Henkel J.S., Beers D.R., Zhao W., Appel S.H. Microglia in ALS: the good, the bad, and the resting. J. Neuroimmune Pharmacol. 2009, 4:389-398.
31. Ilieva H., Polymenidou M., Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009, 187:761-772.
32. Kandinov B., Korczyn A.D., Rabinowitz R., Nefussy B., Drory V.E. Autonomic impairment in a transgenic mouse model of amyotrophic lateral sclerosis. Auton. Neurosci. 2011, 159:84-89.
33. Kandinov B., Drory V.E., Tordjman K., Korczyn A.D. Blood pressure measurements in a transgenic SOD1-G93A mouse model of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2012, 13:509-513.
34. Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., Burrell J.R., Zoing M.C. Amyotrophic lateral sclerosis. Lancet 2011, 377:942-955.
35. Kim W.K., Kan Y., Ganea D., Hart R.P., Gozes I., Jonakait G.M. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. J. Neurosci. 2000, 20:3622-3630.
36. Kim W.K., Ganea D., Jonakait G.M. Inhibition of microglial CD40 expression by pituitary adenylate cyclase-activating polypeptide is mediated by interleukin-10. J. Neuroimmunol. 2002, 126:16-24.
37. Kong J., Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci. 1998, 18:3241-3250.
38. Laburthe M., Couvineau A., Tan V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 2007, 28:1631-1639.
39. Leceta J., Gomariz R.P., Martinez C., Abad C., Ganea D., Delgado M. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Ann. N. Y. Acad. Sci. 2000, 921:92-102.
40. Lerner E.A., Iuga A.O., Reddy V.B. Maxadilan, a PAC1 receptor agonist from sand flies. Peptides 2007, 28:1651-1654.
41. Llewellyn-Smith I.J. Anatomy of synaptic circuits controlling the activity of sympathetic preganglionic neurons. J. Chem. Neuroanat. 2009, 38:231-239.
42. Mertens I., Husson S.J., Janssen T., Lindemans M., Schoofs L. PACAP and PDF signaling in the regulation of mammalian and insect circadian rhythms. Peptides 2007, 28:1775-1783.
43. Mesnard N.A., Sanders V.M., Jones K.J. Differential gene expression in the axotomized facial motor nucleus of presymptomatic SOD1 mice. J. Comp. Neurol. 2011, 519:3488-3506.
44. Miyata A., Arimura A., Dahl R.R., Minamino N., Uehara A., Jiang L., Culler M.D., Coy D.H. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 1989, 164:567-574.
45. Miyata A., Jiang L., Dahl R.D., Kitada C., Kubo K., Fujino M., Minamino N., Arimura A. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem. Biophys. Res. Commun. 1990, 170:643-648.
46. Moisse K., Strong M.J. Innate immunity in amyotrophic lateral sclerosis. Biochim. Biophys. Acta 2006, 1762:1083-1093.
47. Moller K., Reimer M., Ekblad E., Hannibal J., Fahrenkrug J., Kanje M., Sundler F. The effects of axotomy and preganglionic denervation on the expression of pituitary adenylate cyclase activating peptide (PACAP), galanin and PACAP type 1 receptors in the rat superior cervical ganglion. Brain Res. 1997, 775:166-182.
48. Ohtaki H., Nakamachi T., Dohi K., Aizawa Y., Takaki A., Hodoyama K., Yofu S., Hashimoto H., Shintani N., Baba A., Kopf M., Iwakura Y., Matsuda K., Arimura A., Shioda S. Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7488-7493.
49. Okamoto K., Hirai S., Amari M., Iizuka T., Watanabe M., Murakami N., Takatama M. Oculomotor nuclear pathology in amyotrophic lateral sclerosis. Acta Neuropathol. 1993, 85:458-462.
50. Papadeas S.T., Kraig S.E., O'Banion C., Lepore A.C., Maragakis N.J. Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17803-17808.
51. Pettersson L.M., Heine T., Verge V.M., Sundler F., Danielsen N. PACAP mRNA is expressed in rat spinal cord neurons. J. Comp. Neurol. 2004, 471:85-96.
52. Philips T., Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011, 10:253-263.
53. Rat D., Schmitt U., Tippmann F., Dewachter I., Theunis C., Wieczerzak E., Postina R., van Leuven F., Fahrenholz F., Kojro E. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 2011, 25:3208-3218.
54. Reglodi D., Tamás A., Somogyvári-Vigh A., Szántó Z., Kertes E., Lénárd L., Arimura A., Lengvári I. Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia. Peptides 2002, 23:2227-2234.
55. Reglodi D., Tamás A., Lubics A., Szalontay L., Lengvári I. Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats. Regul. Pept. 2004, 123:85-94.
56. Reglódi D., Tamás A., Lengvári I., Toth G., Szalontay L., Lubics A. Comparative study of the effects of PACAP in young, aging, and castrated males in a rat model of Parkinson's disease. Ann. N. Y. Acad. Sci. 2006, 1070:518-524.
57. Reglodi D., Kiss P., Szabadfi K., Atlasz T., Gabriel R., Horvath G., Szakaly P., Sandor B., Lubics A., Laszlo E., Farkas J., Matkovits A., Brubel R., Hashimoto H., Ferencz A., Vincze A., Helyes Z., Welke L., Lakatos A., Tamas A. PACAP is an endogenous protective factor-insights from PACAP-deficient mice. J. Mol. Neurosci. 2012, 48:617-622.
58. Ringer C., Weihe E., Schütz B. Pre-symptomatic alterations in subcellular betaCGRP distribution in motor neurons precede astrogliosis in ALS mice. Neurobiol. Dis. 2009, 35:286-295.
59. Ringer C., Weihe E., Schütz B. Calcitonin gene-related peptide expression levels predict motor neuron vulnerability in the superoxide dismutase 1-G93A mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2012, 45:547-554.
60. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
61. Rothstein J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 2009, 65(Suppl. 1):S3-S9.
62. Schütz B., Reimann J., Dumitrescu-Ozimek L., Kappes-Horn K., Landreth G.E., Schürmann B., Zimmer A., Heneka M.T. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 2005, 25:7805-7812.
63. Seaborn T., Masmoudi-Kouli O., Fournier A., Vaudry H., Vaudry D. Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis. Curr. Pharm. Des. 2011, 17:204-214.
64. Shioda S., Ohtaki H., Nakamachi T., Dohi K., Watanabe J., Nakajo S., Arata S., Kitamura S., Okuda H., Takenoya F., Kitamura Y. Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment. Ann. N. Y. Acad. Sci. 2006, 1070:550-560.
65. Streit W.J. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002, 40:133-139.
66. Streit W.J., Xue Q.S. Life and death of microglia. J. Neuroimmune Pharmacol. 2009, 4:371-379.
67. Stroth N., Liu Y., Aguilera G., Eiden L.E. Pituitary adenylate cyclase-activating polypeptide controls stimulus-transcription coupling in the hypothalamic-pituitary-adrenal axis to mediate sustained hormone secretion during stress. J. Neuroendocrinol. 2011, 23:944-955.
68. Tan Y.V., Abad C., Lopez R., Dong H., Liu S., Lee A., Gomariz R.P., Leceta J., Waschek J.A. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2012-2017.
69. Tomimatsu N., Arakawa Y. Survival-promoting activity of pituitary adenylate cyclase-activating polypeptide in the presence of phosphodiesterase inhibitors on rat motoneurons in culture: cAMP-protein kinase A-mediated survival. J. Neurochem. 2008, 107:628-635.
70. Wang G., Pan J., Tan Y.Y., Sun X.K., Zhang Y.F., Zhou H.Y., Ren R.J., Wang X.J., Chen S.D. Neuroprotective effects of PACAP27 in mice model of Parkinson's disease involved in the modulation of K(ATP) subunits and D2 receptors in the striatum. Neuropeptides 2008, 42:267-276.
71. Weydt P., Yuen E.C., Ransom B.R., Möller T. Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia 2004, 48:179-182.
72. Zhang Y., Malmberg A.B., Sjölund B., Yaksh T.L. The effect of pituitary adenylate cyclase activating peptide (PACAP) on the nociceptive formalin test. Neurosci. Lett. 1996, 207:187-190.
73. Zhou X., Rodriguez W.I., Casillas R.A., Ma V., Tam J., Hu Z., Lelievre V., Chao A., Waschek J.A. Axotomy-induced changes in pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP receptor gene expression in the adult rat facial motor nucleus. J. Neurosci. Res. 1999, 57:953-961.